Viking Therapeutics Inc Stock

From late 2023 to early 2024, Viking Therapeutics (NASDAQ: VKTX) took off like a rocket, as it seemed that the clinical-stage biotech company would become the dark-horse candidate among GLP-1 stocks

Viking Therapeutics (NASDAQ: VKTX) increasingly looks like an acquisition candidate in biotech. But why?

It's because large pharmaceutical companies are desperate to secure obesity drug exposure

The famously volatile biotech industry can help investors earn substantial returns in relatively short periods, so long as they pick the right companies. Take Abivax (NASDAQ: ABVX) and Viking

Eli Lilly (NYSE: LLY) wasn't the first to conquer the weight loss drug market. Novo Nordisk started the ball rolling back in 2017, when it won approval for its GLP-1 drug, Ozempic. Though Ozempic

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) dominate the weight-loss drug market and have for a while. What's more, recent launches are helping them expand this area and attract new patients.

Most stocks would take a hit after a company announces the exit of its founder-CEO on the same morning it posts financial results that fell roughly in line with expectations. Viking Holdings (NYSE:

There's a lot on the minds of Viking Holdings (NYSE: VIK) shareholders heading into this week's financial update. Unlike the more traditional cruise line operators that have already reported this

Investors are turning away from somewhat speculative and unprofitable stocks right now, given the significant volatility and economic-related uncertainty we face. But what if this rotation is

It's not unheard of for biopharma stocks to deliver big gains in relatively short periods; the development of a game-changing drug is usually the catalyst. Even by biopharma standards, though, what

Billionaire investor Warren Buffett has said in the past that "the stock market is a device for transferring money from the impatient to the patient."

While it's easy to get caught up in chasing

Pharmaceutical and biotech companies may offer your portfolio a sense of stability, and this is for one good reason: Patients need their medical treatments, so they will continue going for them

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech company, went public almost 11 years ago. Since then, the drugmaker's stock has performed well, while it has made significant clinical

For stock investors, any beaten-down sector is worth combing through for bargains. These days, healthcare certainly qualifies; the S&P Composite 1500 Health Care index has ticked only marginally

The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to billions of dollars in

Every now and then, two investments land in front of you that look nothing alike but pose the same underlying questions: How much uncertainty are you willing to tolerate, and in what form? In that

Generally, when investors are looking for growth, they turn to industries such as technology. Here, revenue may be rising in the double or even triple digits, leading to explosive stock performance

On February 17, 2026, ACT Capital Management disclosed a new position in Viking Therapeutics (NASDAQ:VKTX), acquiring 206,100 shares worth $7.25 million.

According to an SEC filing dated February

Shares in Vikinig Therapeutics (NASDAQ: VKTX) rose by 16.5% in February, according to data from S&P Global Market Intelligence. The move helped the stock recover in 2026, and at the time of writing,